A Randomized,Subject And Investigator Blind, Sponsor Open Placebo Controlled, Parallel Phase 1b Study To Examine The Safety, Pharmacokinetics, And Pharmacodynamic Effects Of Pf‑06412562 On Cognitive And Reward/Motivation Domains In Healthy Male Volunteers Selected By Cognitive Phenotype

Trial Profile

A Randomized,Subject And Investigator Blind, Sponsor Open Placebo Controlled, Parallel Phase 1b Study To Examine The Safety, Pharmacokinetics, And Pharmacodynamic Effects Of Pf‑06412562 On Cognitive And Reward/Motivation Domains In Healthy Male Volunteers Selected By Cognitive Phenotype

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs PF 6412562 (Primary)
  • Indications Cognition disorders
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Aug 2016 Status changed from active, no longer recruiting to discontinued.
    • 27 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2016.
    • 27 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top